| Overview |
| bs-2526R-Cy7 |
| CD160/By55 Polyclonal Antibody, Cy7 Conjugated |
| WB, FCM, IF(IHC-P) |
| Human, Rat |
| Mouse, Dog |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CD160 |
| 81-159/181 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 11126 |
| O95971 |
| Cell membrane |
| NK1; BY55; NK28; CD160 antigen; Natural killer cell receptor BY55; CD160 |
| CD160, a 27 kDa glycoprotein, was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine rich, glycosylphosphatidylinositol anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz